Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

45.00USD
15 Jun 2018
Change (% chg)

$0.20 (+0.45%)
Prev Close
$44.80
Open
$44.75
Day's High
$45.05
Day's Low
$44.25
Volume
182,795
Avg. Vol
142,214
52-wk High
$45.80
52-wk Low
$10.05

Chart for

About

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008,... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $1,573.80
Shares Outstanding(Mil.): 34.97
Dividend: --
Yield (%): --

Financials

  ZGNX.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -3.56 -- --
ROI: -35.37 -5.87 13.17
ROE: -52.81 -7.71 15.15

BRIEF-Zogenix Q1 Loss Per Share $0.87

* ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER FINANCIAL RESULTS

May 09 2018

BRIEF-Zogenix Inc Q4 Loss Per Share $1.17

* ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 06 2018

BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome

* ZOGENIX COMPLETES ENROLLMENT IN SECOND ZX008 PHASE 3 CLINICAL TRIAL IN DRAVET SYNDROME

Jan 31 2018

BRIEF-Zogenix Says May Issue And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $75.0 Mln

* ZOGENIX INC - MAY ISSUE AND SELL SHARES OF COMMON STOCK HAVING AN AGGREGATE OFFERING PRICE OF UP TO $75.0 MILLION Source text: (http://bit.ly/2kHM2Eb) Further company coverage:

Dec 22 2017

Earnings vs. Estimates